Over the past few decades, a series of innovative medicines have been developed in order
to optimize anticoagulation therapy for atrial fibrillation (AF). As a result, a number of …

Non-vitamin K antagonist oral anticoagulants (NOACs) are commonly used in stroke
prevention in patients with atrial fibrillation. Although the rules for using standard and …

Background: Despite its benefits, oral anticoagulant (OAC) therapy in patients with atrial
fibrillation (AF) is associated with hemorrhagic complication s. Aims: We aimed to evaluate …

Background: Atrial fibrillation (AF) can cause severe symptoms, but it is frequently
asymptomatic. We aimed to compare the clinical features of patients with asymptomatic and …

Background: We aimed to assess characteristics and treatment of AF patients with and
without heart failure (HF). Methods: The prospective, observational Polish Atrial Fibrillation …

Background and Objectives: Atrial fibrillation (AF) is the most common supraventricular
arrhythmia. Currently, catheter ablation is a preferred treatment strategy. The main objective …

Background: The aim of our study was to assess if patients with AF (atrial fibrillation) and a
history of ischemic stroke (IS) excessively receive reduced doses of NOACs (non-vitamin K …

Wstęp. Doustne leki przeciwzakrzepowe (OAC) powinny być stosowane u pacjentów z
migotaniem przedsionków (AF) zależnie od ryzyka zakrzepowo-zatorowego ocenianego za …

Doustne antykoagulanty niebędące antagonistami witaminy K (NOAC, non-vitamin K
antagonist oral anticoagulants) są powszechnie stosowane w prewencji udaru u pacjentów …

A pitvarfibrilláció (PF) a népesség öregedésével egyre gyakoribb, s az iszkémiás stroke
rizikóját ötszörösére emelve jelentősen hozzájárul a stroke-ok nagy számához. A PF okozta …